Cancer testis antigens - Their importance in immunotherapy and in the early detection of cancer

Expert Opinion on Biological Therapy

Volumn 6, Issue 4, 2006, Pages 379-389

  Suri, Anil ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Antigen based vaccine; Biomarkers; Cancer testis antigen; Immunogenicity; Immunotherapy

Indexed keywords

ADAM 2 ANTIGEN; BAGE ANTIGEN; CAGE ANTIGEN; CANCER TESTIS ANTIGEN; GAGE ANTIGEN; MAGE A ANTIGEN; MAGE B ANTIGEN; MAGE C1 ANTIGEN; MELANOMA ANTIGEN; OY TES ANTIGEN; PAGE ANTIGEN; SCP 1 ANTIGEN; SPAG9 ANTIGEN; SPANX ANTIGEN; SSX ANTIGEN; TPTE ANTIGEN; UNCLASSIFIED DRUG; XAGE 1 ANTIGEN;

CANCER; CANCER DIAGNOSIS; CELLULAR IMMUNITY; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNOTHERAPY; REVIEW; SPERMATOGENESIS; TESTIS;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; EARLY DIAGNOSIS; HUMANS; IMMUNOTHERAPY; MALE; TESTICULAR NEOPLASMS;

EID: 33645786274     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.4.379     Document Type: Review

References (99)

1. SAHIN U, TURECI O, SCHMITT H et al.: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA (1995) 92:11810-11813.
2. CHEN YT, SCANLAN MJ, SAHIN U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA (1997) 94:1914-1918.
3. OLD LJ, CHEN YT: New paths in human cancer serology. J. Exp. Med. (1998) 187:1163-1167.
4. SCANLAN MJ, SIMPSON AJ, OLD LJ: The cancer/testis genes: review, standardization, and commentary. Cancer Immun. (2004) 4:1-15. Important review comprising a CT gene database with relevant data regarding their expression profiles, immunogenicity, location and orthologous groups.
5. VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254:1643-1647.
6. SAHIN U, KOSLOWSKI M, TURECI O et al.: Expression of cancer testis genes in human brain tumors. Clin. Cancer Res. (2000) 6:3916-3922.
7. DALERBA P, FRASCELLA E, MACINO B et al.: MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas. Int. J. Cancer (2001) 93:85-90.
8. ZAMBON A, MANDRUZZATO S, PARENTI A et al.: MAGE, BAGE and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia. Cancer (2001) 91:1882-1888.
9. CHAMBOST H, VAN BAREN N, BRASSEUR F et al.: Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood (2000) 95:3530-3533.
10. HEIDECKER L, BRASSEUR F, PROBST-KEPPER M et al.: Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. J. Immunol. (2000) 164:6041-6045.
11. OKAMI J, DOHNO K, SAKON M et al.: Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. Clin. Cancer Res. (2000) 6:2326-2332.
12. OTTE M, ZAFRAKAS M, RIETHDORF L et al.: MAGE-A gene expression pattern in primary breast cancer. Cancer Res. (2001) 61:6682-6687.
13. LADURON S, DEPLUS R, ZHOU S et al.: MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res. (2004) 32:4340-4350.
14. NAGAO T, HIGASHITSUJI H, NONOGUCHI K et al.: MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J. Biol. Chem. (2003) 278:10668-10674.
15. TCHERPAKOV M, BRONFMAN FC, CONTICELLO SG et al.: The p75 neurotrophin receptor interacts with multiple MAGE proteins. J. Biol. Chem. (2002) 277:49101-49104.
16. OHMAN FORSLUND K, NORDQVIST K et al.: The melanoma antigen genes-any clues to their functions in normal tissues? Exp. Cell Res. (2001) 265:185-194.
17. JUNGBLUTH AA, ELY S, DILIBERTO M et al.: The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood (2005) 106:167-174. Description of the expression of the MAGE family genes in multiple myeloma patients and their correlation with cellular proliferation.
18. SUGITA Y, WADA H, FUJITA S et al.: NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res. (2004) 64:2199-2204.
19. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc. Natl. Acad. Sci. USA (2003) 100:8862-8867.
20. + T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. (2003) 3:15-23.
21. JUNGBLUTH AA, CHEN YT, STOCKERT E et al.: Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int. J. Cancer (2001) 92:856-860.
22. SARCEVIC B, SPAGNOLI GC, TERRACCIANO L et al.: Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology (2003) 64:443-449.
23. KIENSTRA MA, NEEL HB, STROME SE et al.: Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck (2003) 25:457-463.
24. MAIO M, CORAL S, SIGALOTTI L et al.: Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J. Clin. Endocrinol. Metab. (2003) 88:748-754.
25. VAN RHEE F, SZMANIA SM, ZHAN F et al.: NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood (2005) 105:3939-3944.
26. JAGER E, CHEN YT, DRIJFHOUT JW et al.: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. (1998) 187:265-270.
27. GNJATIC S, NAGATA Y, JAGER E et al.: Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl. Acad. Sci. USA (2000) 97:10917-10922.
28. MANDIC M, CASTELLI F, JANJIC B et al.: One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol. (2005) 174:1751-1759. An important study of an NY-ESO-1-derived epitope capable of generating cell-mediated immunity
29. LETHE B, LUCAS S, MICHAUX L et al.: LAGE-1, a new gene with tumor specificity. Int. J. Cancer (1998) 76:903-908.
30. VAUGHAN HA, SVOBODOVA S, MACGREGOR D et al.: Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin. Cancer Res. (2004) 10:8396-8404.
31. BOON T, VAN DER BRUGGEN P: Human tumor antigens recognized by T lymphocytes. J. Exp. Med. (1996) 183:725-729.
32. RUAULT M, VENTURA M, GALTIER N et al.: BAGE genes generated by juxtacentromeric reshuffling in the Hominidae lineage are under selective pressure. Genomics (2003) 81:391-399.
33. VAN DEN EYNDE B, PEETERS O, DE BACKER O et al.: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. (1995) 182:689-698.
34. DUAN Z, DUAN Y, LAMENDOLA DE et al.: Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin. Cancer Res. (2003) 9:2778-2785.
35. BRINKMANN U, VASMATZIS G, LEE B et al.: PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. Proc. Natl. Acad. Sci. USA (1998) 95:10757-10762.
36. MARCHAND M, WEYNANTS P, RANKIN E et al.: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer (1995) 63:883-885.
37. BRINKMANN U, VASMATZIS G, LEE B, PASTAN I: Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res. (1999) 59:1445-1448.
38. LIU XF, HELMAN LJ, YEUNG C, BERA TK, LEE B, PASTAN I: XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma. Cancer Res. (2000) 60:4752-4755.
39. ZENDMAN AJ, VAN KRAATS AA, WEIDLE UH, RUITER DJ, VAN MUIJEN GN: The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma. Int. J. Cancer (2002) 99:361-369.
40. EGLAND KA, KUMAR V, DURAY P, PASTAN I: Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol. Cancer Ther. (2002) 1:441-450.
41. ALI ELDIB AM, ONO T, SHIMONO M et al.: Immunoscreening of a cDNA library from a lung cancer cell line using autologous patient serum: identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma. Int. J. Cancer (2004) 108:558-563.
42. NAKAGAWA K, NOGUCHI Y, UENAKA A et al.: XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin. Cancer Res. (2005) 11:5496-5503.
43. DAVIS ID, CHEN W, JACKSON H et al.: Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl. Acad. Sci. USA (2004) 101:10697-10702.
44. SHANKAR S, MOHAPATRA B, SURI A: Cloning of a novel human testis mRNA specifically expressed in testicular haploid germ cells, having unique palindromic sequences and encoding a leucine zipper dimerization motif. Biochem. Biophys. Res. Commun. (1998) 243:561-565.
45. JAGADISH N, RANA R, SELVI R et al.: Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein. Biochem. J. (2005) 389:73-82. This study describes the molecular and biochemical characterisation of SPAG9.
46. WILLIS S, HUTCHINS AM, HAMMET F et al.: Detailed gene copy number and RNA expression analysis of the 17q12-23 region in primary breast cancers. Genes Chromosomes Cancer (2003) 36:382-392.
47. KITAHARA O, KATAGIRI T, TSUNODA T, HARIMA Y, NAKAMURA Y: Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia (2002) 4:295-303.
48. LINN SC, WEST RB, POLLACK JR et al.: Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am. J. Pathol. (2003) 163:2383-2395.
49. HELM J, ENKEMANN SA, COPPOLA D et al.: Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Clin. Cancer Res. (2005) 11:2478-2485.
50. MCLESKEY SB, DOWDS C, CARBALLADA R, WHITE RR, SALING PM: Molecules involved in mammalian sperm-egg interaction. Int. Rev. Cytol. (1998) 177:57-113.
51. STRAUGHN JM JR, SHAW DR, GUERRERO A et al.: Expression of sperm protein 17 (Sp17) in ovarian cancer. Int. J. Cancer (2004) 108:805-811.
52. CHIRIVA-INTERNATI M, WANG Z, SALATI E, TIMMINS P, LIM SH: Tumor vaccine for ovarian carcinoma targeting sperm protein 17. Cancer (2002) 94:2447-2453.
53. LIM SH, WANG Z, CHIRIVA-INTERNATI M, XUE Y: Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood (2001) 97:1508-1510.
54. LIM SH, BUMM K, CHIRIVA-INTERNATI M, XUE Y, WANG Z: MAGE-C1 (CT7) gene expression in multiple myeloma: relationship to sperm protein 17. Eur. J. Haematol. (2001) 67:332-334.
55. GRIZZI F, GAETANI P, FRANCESCHINI B et al.: Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer (2006) 6:23-47.
56. CHIRIVA-INTERNATI M, WANG Z, SALATI E, BUMM K, BARLOGIE B, LIM SH: Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood (2002) 100:961-965.
57. MEUWISSEN RL, OFFENBERG HH, DIETRICH AJ et al.: A coiled-coil related protein specific for synapsed regions of meiotic prophase chromosomes. EMBO J. (1992) 11:5091-5100.
58. TURECI O, SAHIN U, ZWICK C, KOSLOWSKI M, SEITZ G, PFREUNDSCHUH M: Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc. Natl. Acad. Sci. USA (1998) 95:5211-5216.
59. KALEJS M, ERENPREISA J: Cancer/testis antigens and gametogenesis: a review and 'brain-storming' session. Cancer Cell Int. (2005) 5:4-14.
60. TAMMELA J, JUNGBLUTH AA, QIAN F et al.: SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Cancer Immun. (2004) 4:10-21.
61. BABA T, NIIDA Y, MICHIKAWA Y et al.: An acrosomal protein, sp32, in mammalian sperm is a binding protein specific for two proacrosins and an acrosin intermediate. J. Biol. Chem. (1994) 269:10133-10140.
62. ONO T, KURASHIGE T, HARADA N et al.: Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc. Natl. Acad. Sci. USA (2001) 98:3282-3287.
63. IWATA T, FUJITA T, HIRAO N et al.: Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability-positive endometrial cancer. Clin. Cancer Res. (2005) 11:3949-3957.
64. ISHIKAWA T, FUJITA T, SUZUKI Y et al.: Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res. (2003) 63:5564-5572.
65. ALSHEIMER M, DREWES T, SCHUTZ W, BENAVENTE R: The cancer/testis antigen CAGE-1 is a component of the acrosome of spermatids and spermatozoa. Eur. J. Cell Biol. (2005) 84:445-452. CT antigen with a possible role in fertilisation.
66. YOSHINAGA K, TOSHIMORI K: Organization and modifications of sperm acrosomal molecules during spermatogenesis and epididymal maturation. Microsc. Res. Tech. (2003) 61:39-45.
67. TULSIANI DR, ABOU-HAILA A: Mammalian sperm molecules that are potentially important in interaction with female genital trace and egg vestments. Zygote (2001) 9:51-69.
68. PARK S, LIM Y, LEE D et al.: Identification and characterization of a novel cancer/testis antigen gene CAGE-1. Biochim. Biophys. Acta (2003) 1625:173-182.
69. WESTBROOK VA, SCHOPPEE PD, DIEKMAN AB et al.: Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines. Clin. Cancer Res. (2004) 10:101-112.
70. WESTBROOK VA, DIEKMAN AB, KLOTZ KL et al.: Spermatid-specific expression of the novel X-linked gene product SPAN-X localized to the nucleus of human spermatozoa. Biol. Reprod. (2000) 63:469-481.
71. ERENPREISA J, IVANOV A, CRAGG M, SELIVANOVA G, ILLIDGE T: Nuclear envelope-limited chromatin sheets are part of mitotic death. Histochem. Cell Biol. (2002) 117:243-255.
72. TAPPAREL C, REYMOND A, GIRARDET C et al.: The TPTE gene family: cellular expression, subcellular localization and alternative splicing. Gene (2003) 323:189-199.
73. SINGHAL PK, QIAN F, KEITZ B et al.: TPTE 'Cancer/Testis' antigen is a candidate target for immunotherapy in epithelial ovarian carcinoma. J. Clin. Oncol. (2005) 23(Suppl. 16):2583.
74. PRIMAKOFF P, MYLES DG: The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet. (2000) 16:83-87.
75. LOECHEL F, GILPIN BJ, ENGVALL E, ALBRECHTSEN R, WEWER UM: Human ADAM 12 (meltrin a) is an active metalloprotease. J. Biol. Chem. (1998) 273:16993-16997.
76. SCHLÖNDORFF J, BLOBEL CP: Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J. Cell Sci. (1999) 112:3603-3617.
77. LOPEZ-PEREZ E, ZHANG Y, FRANK SJ et al.: Constitutive alpha-secretase cleavage of the beta-amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the pro-hormone convertase 7 and the disintegrin metalloprotease ADAM 10. J. Neurochem. (2001) 76:1532-1539.
78. MCCULLOCH DR, HARVEY M, HERINGTON AC: The expression of the ADAMs proteases in prostate cancer cell lines and their regulation by dihydrotestosterone. Mol. Cell Endocrinol. (2000) 167:11-21.
79. GUTWEIN P, OLESZEWSKI M, MECHTERSHEIMER S, AGMON-LEVIN N, KRAUSS K, ALTEVOGT P: Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J. Biol. Chem. (2000) 275:15490-15497.
80. KHATIB AM, SIEGFRIED G, CHRETIEN M, METRAKOS P, SEIDAH NG: Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am. J. Pathol. (2002) 160:1921-1935.
81. CLARK J, ROCQUES PJ, CREW AJ et al.: Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat. Genet. (1994) 7:502-508.
82. GURE AO, WEI IJ, OLD LJ et al.: The SSX gene family: characterization of 9 complete genes. Int. J. Cancer (2002) 101:448-453.
83. GURE AO, TURECI O, SAHIN U et al.: SSX: a multigene family with several members transcribed in normal testis and human cancer. Int. J. Cancer (1997) 72:965-971.
84. VALMORI D, QIAN F, AYYOUB M et al.: Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin. Cancer Res. (2006) 12:398-404.
85. LI M, YUAN YH, HAN Y et al.: Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin. Cancer Res. (2005) 11:1809-1814.
86. BODEY B: Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy. Expert Opin. Biol. Ther. (2002) 2(6):577-584. Important review about CT antigens as promising targets for immunotherapy.
87. OTTE M, ZAFRAKAS M, RIETHDORF L et al.: MAGE-A gene expression pattern in primary breast cancer. Cancer Res. (2001) 61:6682-6687.
88. KURASHIGE T, NOGUCHI Y, SAIKA T et al.: Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res. (2001) 61:4671-4674.
89. FUJITA S, WADA H, JUNGBLUTH AA et al.: NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin. Cancer Res. (2004) 10:6551-6558.
90. KONISHI J, TOYOOKA S, AOE M et al.: The relationship between NY-ESO-1 mRNA expression and clinicopathological features in non-small cell lung cancer. Oncol. Rep. (2004) 11:1063-1067.
91. STOCKERT E, JAGER E, CHEN YT et al.: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. (1998) 187:1349-1354.
92. JAGER E, JAGER D, KNUTH A: Strategies for the development of vaccines to treat breast cancer. Recent Res. Cancer Res. (1998) 152:94-102.
93. MUSCATELLI F, WALKER AP, DE PLAEN E et al.: Isolation and characterization of a MAGE gene family in the Xp21.3 region. Proc. Natl. Acad. Sci. USA (1995) 92:4987-4991.
94. LUCAS S, DE SMET C, ARDEN KC et al.: Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res. (1998) 58:743-752.
95. OKUMURA H, NOGUCHI Y, UENAKA A et al.: Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells. Microbiol. Immunol. (2005) 49:1009-1016.
96. CHO B, LIM Y, LEE DY et al.: Identification and characterization of a novel cancer/testis antigen gene CAGE. Biochem. Biophys. Res. Commun. (2002) 292:715-726.
97. WANG Z, ZHANG Y, LIU H et al.: Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood (2003) 101:955-960.
98. DONG XY, SU YR, QIAN XP et al.: Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients. Br. J. Cancer (2003) 89:291-297.
99. SCANLAN MJ, GORDON CM, WILLIAMSON B et al.: Identification of cancer/testis genes by database mining and mRNA expression analysis. Int. J. Cancer (2002) 98:485-492.